Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

vaccine trials

- PMLiVE

Moderna deal to build state-of-the-art manufacturing plant bolsters Canada’s vaccine production

The new manufacturing facility will enhance the country’s “rapid pandemic response capabilities”

- PMLiVE

AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria

Real-world data shows similar safety profile for Vaxzevria and mRNA-based jabs

- PMLiVE

AZ raises full-year guidance after completing Alexion acquisition in Q2

Total revenue was up by 31% to $8.2bn and also increased by 24% to $15.2bn for the half year

- PMLiVE

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone

- PMLiVE

Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels

South Korea-based study found AZ followed by Pfizer boosted antibody levels six-fold compared to two AZ doses

- PMLiVE

AZ’s PNH therapy Ultomiris wins EU backing to expand use for children

The positive recommendation is based on interim results from a phase 3 trial

- PMLiVE

One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants

New real-world data from Canada shows vaccine efficacy was lower against milder symptomatic disease with one dose

Investigating the Complexities of the Canadian & Global Health Systems

The Honourable Tony Clement, Co-chair at Reshoring Canada and former Minister of Health, discusses digital transformation, the importance of onshore manufacturing and supply chain operations in Canada, current pharmaceutical regulatory...

Impetus Digital

- PMLiVE

EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine

Rolling review launched based on preliminary results from lab studies and early clinical studies

- PMLiVE

AZ licenses pneumonia mAb to Aridis Pharmaceuticals for $11m upfront

The candidate – suvratoxumab – is ready for phase 3 clinical evaluation for the prevention of pneumonia

- PMLiVE

FDA advisory committee votes against approval of AZ, FibroGen’s roxadustat

Briefing documents published earlier this week raised questions over the safety profile of roxadustat

- PMLiVE

AZ, J&J to research modifications to COVID-19 vaccines over rare blood clot issues

Researchers to explore potential of modifications to vaccine to reduce or remove risk of rare blood clots

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links